Short-term safety and efficacy of switching from alemtuzumab to ocrelizumab in MS patients with disease activity after two alemtuzumab courses: an Italian multicentric, real-life study.

被引：0
|
作者：
Lapucci, C.
Frau, J. [1 ]
Cocco, E.
Vercellino, M.
Cavalla, P.
Petracca, M.
Lanzillo, R.
Grossi, P. [2 ]
Ferro, M. T. [3 ]
Guaschino, C. [4 ]
Zaffaroni, M. [5 ]
Tazza, F. [6 ]
Novi, G.
Uccelli, A.
Inglese, M. [7 ]
机构：
[1] Univ Cagliari, Dept Med Sci & Publ Hlth, Multiple Sclerosis Ctr, Binaghi Hosp, Cagliari, Italy
[2] Univ Padua, Padua, Italy
[3] Osped Maggiore Crema, Neurol Dept, Multiple Sclerosis Ctr, Neuroimmunol, Crema, Italy
[4] Multiple Sclerosis Study Ctr, Neurol Dept, Gallarate, Italy
[5] Gallarate Hosp, Multiple Sclerosis Ctr, ASST Valle Olona, Gallarate, VA, Italy
[6] IRCCS Osped San Martino, Genoa, Italy
[7] Univ Genoa, Neurosci, Genoa, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2263
引用
收藏
页码：929 / 929
页数：1
相关论文
共 43 条
  • [1] Short-term evaluation of alemtuzumab to ocrelizumab switch in ms patients with disease activity after alemtuzumab: an italian multicentric study
    Lapucci, C.
    Frau, J.
    Cocco, E.
    Cavalla, P.
    Vercellino, M.
    Petracca, M.
    Lanzillo, R.
    Grossi, P.
    Ferro, M. T.
    Guaschino, C.
    Zaffaroni, M.
    Tazza, F.
    Novi, G.
    Uccelli, A.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 195 - 196
  • [2] Short-term evaluation of alemtuzumab to ocrelizumab switch in MS patients with disease activity after alemtuzumab: an Italian multicentric study
    Lapucci, Caterina
    Frau, Jessica
    Cocco, Eleonora
    Vercellino, Marco
    Cavalla, Paola
    Petracca, Maria
    Lanzillo, Roberta
    Grossi, Paola
    Ferro, Maria Teresa
    Zaffaroni, Mauro
    Tazza, Francesco
    Novi, Giovanni
    Uccelli, Antonio
    Inglese, Matilde
    NEUROLOGY, 2021, 96 (15)
  • [3] A real life, multicenter, observational study to evaluate safety and efficacy of the switch from alemtuzumab to ocrelizumab in MS patient with evidence of disease activity after two alemtuzumab courses: the italian experience
    Lapucci, Caterina
    Frau, Jessica
    Cocco, Eleonora
    Coghe, Giancarlo
    Petracca, Maria
    Lanzillo, Roberta
    Vercellino, Marco
    Cavalla, Paola
    Bianco, Assunta
    Mirabella, Massimiliano
    Di Mauro, Giovanni
    Landi, Doriana
    Marfia, Girolama Alessandra
    Clerici, Valentina Torri
    Roldan, Eugenia Tomas
    Ferro, Maria Teresa
    Grossi, Paola
    Zaffaroni, Mauro
    Ronzoni, Marco
    Nozzolillo, Agostino
    Moiola, Lucia
    Pinardi, Federica
    Novi, GIovanni
    Cellerino, Maria
    Antonio, Ucccelli
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 441 - 442
  • [4] Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study
    Lapucci, Caterina
    Frau, Jessica
    Cocco, Eleonora
    Coghe, Giancarlo
    Petracca, Maria
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Nicoletti, Carolina Gabri
    Landi, Doriana
    Marfia, Girolama
    Vercellino, Marco
    Cavalla, Paola
    Bianco, Assunta
    Mirabella, Massimiliano
    Clerici, Valentina Torri
    Tomas, Eugenia
    Ferro, Maria Teresa
    Grossi, Paola
    Nozzolillo, Agostino
    Moiola, Lucia
    Zaffaroni, Mauro
    Ronzoni, Marco
    Pinardi, Federica
    Novi, Giovanni
    Cellerino, Maria
    Uccelli, Antonio
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1151 - 1162
  • [5] Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity after the Initial Two Courses: Results from the CARE-MS II Extension
    Boster, Aaron
    Traboulsee, Anthony
    Bass, Ann D.
    Berkovich, Regina
    Comi, Giancarlo
    Fernandez, Oscar
    Kim, Ho Jin
    Limmroth, Volker
    Lycke, Jan
    Macdonell, Richard
    Sharrack, Basil
    Vermersch, Patrick
    Wiendl, Heinz
    Ziemssen, Tjalf
    Melanson, Maria
    Daizadeh, Nadia
    Singer, Barry A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 26 - 27
  • [6] EFFICACY AND SAFETY OF UPADACITINIB IN RHEUMATHOID ARTHRITIS: REAL-LIFE EXPERIENCE FROM A MULTICENTRIC ITALIAN STUDY
    Baldi, C.
    Parisi, S.
    Falsetti, P.
    Nacci, F.
    Ditto, M. C.
    D'alessandro, M.
    Capassoni, M.
    Sota, J.
    Conticini, E.
    Peroni, C. L.
    Cometi, L.
    Fusaro, E.
    Frediani, B.
    Guiducci, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1431 - 1432
  • [7] Efficacy of a fourth alemtuzumab course in RRMS patients with disease activity after three prior courses: analysis of CARE-MS I
    Wiendl, H.
    Alroughani, R.
    Boster, A.
    Traboulsee, A.
    Bass, A. D.
    Berkovich, R.
    Comi, G.
    Fernandez, O.
    Kim, H. J.
    Limmroth, V.
    Lycke, J.
    Macdonell, R.
    Sharrack, B.
    Vermersch, P.
    Ziemssen, T.
    Melanson, M.
    Daizadeh, N.
    Singer, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 531 - 531
  • [8] Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study)
    Oreja-Guevara, C.
    Alroughani, R.
    Brassat, D.
    Boyko, A. N.
    McCombe, P.
    Steingo, B.
    Van Wijmeersch, B.
    Margolin, D. H.
    Daizadeh, N.
    Rodriguez, C. E.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 629 - 629
  • [9] Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina
    Salkic, Nermin
    Denjagic, Mirela Basic
    Zubcevic, Nada
    Tamburic, Renata
    Husic Selimovic, Azra
    Babic, Emil
    Bevanda, Milenko
    Saray, Aida
    Jovanovic, Predrag
    Tosic, Zoran
    Dobrovoljski, Aleksandar
    Barac, Tatjana
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (05): : 1400 - 1406
  • [10] Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after two courses: analysis of patients who received ≥3 courses
    Traboulsee, A.
    Bass, A. D.
    Boster, A.
    Berkovich, R.
    Comi, G.
    Fernandez, O.
    Kim, H. J.
    Limmroth, V.
    Lycke, J.
    Macdonell, R. A. L.
    Schippling, S.
    Vermersch, P.
    Wiendl, H.
    Ziemssen, T.
    Chung, L.
    Daizadeh, N.
    Rodriguez, C. E.
    Singer, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 517 - 518
12345